Saturday, 25 November 2017

Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study

  1. Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study  Business Wire (press release)Full coverage
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)